moxifloxacin has been researched along with Diarrhea in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YB; Fang, YH; Gu, SL; Li, LJ; Lv, T; Shen, P; Tang, LL | 1 |
| Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC | 1 |
| Forbes, BA; Gerding, DN; Goldstein, EJ; Jacobus, NV; Jenkins, SG; Johnson, S; McDermott, LA; Mirrett, S; Patel, R; Snydman, DR; Stone, S; Thorpe, C | 1 |
| del Mar Gamboa-Coronado, M; López-Ureña, D; Montoya-Ramírez, M; Quesada-Gómez, C; Rodríguez, C; Rodríguez-Cavallini, E; Somogyi, T | 1 |
| Abratt, V; Kullin, B; Reid, SJ; Wojno, J | 1 |
| Simoens, S | 1 |
| Carman, RJ; Genheimer, CW; Hiltonsmith, MF; Lyerly, DM; Park, M; Rafii, F | 1 |
| Baral, RM; Gottlieb, S; Govendir, M; Hansen, T; Kimble, B; Malik, R; Norris, JM; Wigney, DI | 1 |
| Kang, JO; Kim, J; Pai, H; Seo, MR | 1 |
| Farina, C; Russello, G; Russo, A; Scaltrito, MM; Sisto, F | 1 |
| López, R; Ortiz-de-Saracho, J; Pantoja, L; Romero, MJ | 1 |
| Carroll, DN | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
1 review(s) available for moxifloxacin and Diarrhea
| Article | Year |
|---|---|
Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Topics: Anti-Bacterial Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Cost-Benefit Analysis; Diarrhea; Drug Resistance, Microbial; Economics, Pharmaceutical; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Practice Guidelines as Topic; Quinolines | 2009 |
12 other study(ies) available for moxifloxacin and Diarrhea
| Article | Year |
|---|---|
Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
Topics: Anti-Infective Agents; Bacterial Proteins; China; Clindamycin; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Moxifloxacin; Tertiary Care Centers; Vancomycin | 2018 |
Antituberculosis Treatment in a Patient with Celiac Disease.
Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2018 |
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Clindamycin; Clostridioides difficile; Diarrhea; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Fluoroquinolones; Genes, Bacterial; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multiplex Polymerase Chain Reaction; Prohibitins; Sentinel Surveillance; United States; Vancomycin | 2015 |
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Clostridium Infections; Communicable Diseases, Emerging; Costa Rica; Cross Infection; Diarrhea; Disease Outbreaks; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterocolitis, Pseudomembranous; Fluoroquinolones; Genes, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Ribotyping; Time Factors; Vancomycin | 2016 |
Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Child; Child, Preschool; Clostridioides difficile; Clostridium Infections; Diarrhea; Disk Diffusion Antimicrobial Tests; Enterotoxins; Erythromycin; Female; Fluoroquinolones; Hospitals, Chronic Disease; Humans; Infant; Infant, Newborn; Male; Middle Aged; Minisatellite Repeats; Molecular Epidemiology; Moxifloxacin; Ribotyping; Rifampin; South Africa; Young Adult | 2017 |
Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
Topics: Anti-Bacterial Agents; Aza Compounds; Clostridioides difficile; Cross Infection; Diarrhea; Disease Outbreaks; DNA Gyrase; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Genetic Variation; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Ribotyping | 2009 |
Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Australia; Aza Compounds; Cats; Ciprofloxacin; Diarrhea; Dogs; Enrofloxacin; Female; Fluoroquinolones; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Quinolines | 2011 |
Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clindamycin; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Resistance, Microbial; Enterotoxins; Feces; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Risk Factors; Severity of Illness Index; Treatment Outcome | 2012 |
Laboratory diagnosis of Clostridium difficile associated diarrhoea and molecular characterization of clinical isolates.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Resistance, Bacterial; Enterotoxins; Feces; Female; Fluoroquinolones; Genes, Bacterial; Glutamate Dehydrogenase; Humans; Immunoenzyme Techniques; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Prevalence; Quinolines; Ribotyping; Sensitivity and Specificity; Young Adult | 2012 |
Moxifloxacin-induced Clostridium difficile diarrhea.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines | 2003 |
Moxifloxacin-induced Clostridium difficile-associated diarrhea.
Topics: Adult; Aza Compounds; Clostridioides difficile; Diarrhea; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines | 2003 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |